Saxenda vs Ozempic side effects: what the data actually shows

What's this video probably claiming?

Based on the caption responding to a user question about Saxenda (liraglutide) and Ozempic (semaglutide) symptoms, this creator, who appears to operate in the bariatric surgery space given the gastric sleeve and bypass hashtags, is likely comparing side effect profiles of these two GLP-1 receptor agonists. The framing suggests a clinical or educational tone, possibly distinguishing which drug causes more nausea, vomiting, or gastrointestinal distress. There may also be commentary on how these medications interact with or compare to surgical options like gastric sleeve. The account's bariatric focus makes it plausible they're speaking to patients who use GLP-1s either as surgical alternatives or as post-surgical adjuncts. That's a legitimate clinical conversation, but the details matter enormously, and social media summaries of drug side effects often flatten the nuance in ways that can mislead patients about what to expect or what to report to their prescriber.

What does the science actually show?

Both liraglutide (Saxenda, 3.0 mg/day subcutaneous) and semaglutide (Ozempic, up to 2.0 mg/week for weight) are GLP-1 receptor agonists, but they are not interchangeable in their tolerability profiles. The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM) showed liraglutide 3.0 mg produced nausea in roughly 39% of participants and vomiting in about 15%, with most GI symptoms peaking in the first 4-8 weeks. Semaglutide data from the STEP 1 trial (Wilding et al., 2021, NEJM) showed nausea in approximately 44% and vomiting in 24% of participants using 2.4 mg weekly, with a similar early-onset pattern. Semaglutide's once-weekly dosing versus liraglutide's daily injection changes the peak-trough dynamics of side effects. Neither drug is clearly easier on the stomach for every patient, and individual response varies substantially based on titration speed, meal size, and baseline GI sensitivity.

Where does the social media noise diverge from clinical reality?

The biggest problem with GLP-1 side effect content on TikTok is the normalization of severe symptoms. Persistent vomiting, inability to tolerate fluids, and significant abdominal pain are not just "part of the process." They can indicate pancreatitis, gastroparesis exacerbation, or severe dehydration requiring medical attention. A 2023 pharmacovigilance analysis published in JAMA Internal Medicine (Sodhi et al., 2023) found semaglutide and liraglutide users had significantly higher rates of gastroparesis, pancreatitis, and bowel obstruction compared to bupropion-naltrexone users. Creators comparing these drugs often omit that semaglutide's longer half-life means side effects can persist longer if they emerge. There's also a tendency in bariatric communities to frame GLP-1 side effects as evidence the drug is "working," which is not supported by mechanism. Nausea reflects receptor activation in the gut and brainstem, not fat metabolism. Suffering more does not mean losing more weight.

What should you actually know?

If you're choosing between or transitioning between these medications, the side effect comparison is real and worth discussing with a prescriber, but not something to manage based on a TikTok response video. Titration schedules exist for a reason. Both drugs require slow dose escalation specifically to reduce GI burden, and skipping that protocol because a video made the drug sound manageable is a common reason people discontinue early. The STEP 5 trial (Garvey et al., 2022, Nature Medicine) showed that patients who completed 104 weeks on semaglutide 2.4 mg maintained an average 15.2% body weight reduction, but dropout due to adverse events was non-trivial. If you've had bariatric surgery, your GI anatomy is already altered, and GLP-1 side effect risk may be different from the general population studied in these trials. That clinical nuance rarely makes it into a short-form video.